The Systemic Sclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Systemic Sclerosis: An Overview
Systemic Sclerosis (SSc) is an autoimmune disease affecting the connective tissue which in turn damages the skin and internal organs. It is characterized by a distinctive pathogenic triad of microvascular damage, deregulation of innate and adaptive immunity, and generalized fibrosis in multiple organs. Lung fibrosis (interstitial lung disease) and pulmonary arterial hypertension (PAH) are the two leading causes of mortality in Systemic Sclerosis.
Systemic sclerosis is classified into two subsets based on the extent of skin involvement – limited systemic sclerosis (lcSSc) and diffuse systemic sclerosis (dsSSc). Patients with fibrosis of the skin affecting acral parts of the body – face and limbs (distal to the knees and elbows) – are classified as having lcSSc, whereas those with fibrosis of the trunk and proximal parts of the limbs are classified as having dsSSc.
As per the study by Schwartz et al. (2018), Systemic Sclerosis is a rare disease and is diagnosed in approximately 67 male patients and 265 female patients, per 100,000 people each year in the United States.
Systemic Sclerosis Market Key Facts
-
As per the National Organization for Rare Disorders (2018), systemic scleroderma is thought to affect 40,000–165,000 people in the US. It may occur at any age, but the symptoms most frequently begin during midlife.
-
As per the literature review by Chifflot et al. (2018), many geographical variations exist in SSc prevalence, such as a higher number of cases in the USA (276/million) than in Japan and Europe, where a north-south gradient was clearly observed (France: 158/million in 2001 and England: 88/million in 2000).
-
According to DelveInsight, women are four times more likely to develop Systemic Sclerosis as compared to men.
-
SSc usually appears in women aged 30–40, and it occurs in slightly older men. In approximately 85% of cases, systemic sclerosis develops in individuals aged 20–60 years.
The Systemic Sclerosis (SSc) market size is anticipated to increase during the study period owing to the increasing prevalent population in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Systemic Sclerosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Systemic Sclerosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Systemic Sclerosis Epidemiology
The epidemiology section covers insights about the historical and current Systemic Sclerosis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Systemic Sclerosis Epidemiology Segmentation –
-
Prevalent Cases of Systemic Sclerosis (SSc)
-
Prevalent cases of SSc based on Clinical Manifestations
-
Type-specific Cases of Systemic Sclerosis (SSc)
-
Age-specific Cases of Systemic Sclerosis (SSc)
Systemic Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis market or expected to get launched in the market during the study period. The analysis covers Systemic Sclerosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Systemic Sclerosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/systemic-sclerosis-market
Systemic Sclerosis Therapeutics Analysis
There are a number of treatments that can be effective in Systemic Sclerosis; however, they have many limitations. Most of the therapies have some adverse effects, and there is no single accepted medical treatment for aggressive fibromatosis. Thus, there is a high urgent demand for novel therapies that can overcome the limitations of existing therapies.
To fulfill the unmet need at present some of the key players at the global level are diligently involved in the development of therapies for the treatment of Systemic Sclerosis (SSc).
Some of the key companies in the Systemic Sclerosis Market include:
-
Forbius
-
Novartis
-
Genentech
-
Galapagos NV
-
GNI Group
-
CSL Behring
-
Seattle Genetics
-
Kyowa Hakko Kirin
-
GlaxoSmithKline
-
Corbus Pharmaceuticals
-
Kaken Pharmaceutical
-
Fibrocell, Kadmon Corporation
-
Cumberland Pharmaceuticals
And many others
Systemic Sclerosis Therapies Covered in the report include:
-
Lenabasum
-
Pirfenidone
-
GLPG1690
-
Brodalumab
-
GSK2330811
-
KD025
-
Vasculan
-
FCX-013
-
AVID200
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/systemic-sclerosis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Systemic Sclerosis Competitive Intelligence Analysis
4. Systemic Sclerosis Market Overview at a Glance
5. Systemic Sclerosis Disease Background and Overview
6. Systemic Sclerosis Patient Journey
7. Systemic Sclerosis Epidemiology and Patient Population
8. Systemic Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Sclerosis Unmet Needs
10. Key Endpoints of Systemic Sclerosis Treatment
11. Systemic Sclerosis Marketed Products
12. Systemic Sclerosis Emerging Therapies
13. Systemic Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Systemic Sclerosis Market Outlook (7 major markets)
16. Systemic Sclerosis Access and Reimbursement Overview
17. KOL Views on the Systemic Sclerosis Market.
18. Systemic Sclerosis Market Drivers
19. Systemic Sclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/systemic-sclerosis-market
Other Trending Healthcare Reports By DelveInsight
Malignant Pleural Mesothelioma (MPM) Market
Malignant Pleural Mesothelioma (MPM) Market is anticipated to grow in the coming years owing to the improvement in healthcare spending across the world, rising prevalence, and the active participation of the key companies in the therapeutics domain such as Sellas, Polaris Pharma, Targovax, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/